SI2632927T1 - Boronati kot inhibitorji arginaze - Google Patents

Boronati kot inhibitorji arginaze

Info

Publication number: SI2632927T1
Authority: SI; Slovenia
Prior art keywords: boronates; arginase inhibitors; arginase; inhibitors
Prior art date: 2010-10-26

Application number

SI201130766A

Other languages

English (en)

Inventor

Zandt Michael Van

Jr. Gunnar Erik Jagdmann

Original Assignee

Mars, Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-26

Filing date

2011-10-19

Publication date

2016-08-31

2011-10-19 Application filed by Mars, Incorporated filed Critical Mars, Incorporated

2016-08-31 Publication of SI2632927T1 publication Critical patent/SI2632927T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SI201130766A 2010-10-26 2011-10-19 Boronati kot inhibitorji arginaze SI2632927T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US40676010P	2010-10-26	2010-10-26
PCT/US2011/056844 WO2012058065A1 (en)	2010-10-26	2011-10-19	Boronates as arginase inhibitors
EP11779904.9A EP2632927B1 (en)	2010-10-26	2011-10-19	Boronates as arginase inhibitors

Publications (1)

Publication Number	Publication Date
SI2632927T1 true SI2632927T1 (sl)	2016-08-31

Family

ID=44913403

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201130766A SI2632927T1 (sl)	2010-10-26	2011-10-19	Boronati kot inhibitorji arginaze

Country Status (19)

Country	Link
US (5)	US9233985B2 (sl)
EP (3)	EP3719024A1 (sl)
JP (1)	JP5909239B2 (sl)
CN (2)	CN106008569B9 (sl)
AU (1)	AU2011320732B2 (sl)
BR (1)	BR112013010099B1 (sl)
CA (1)	CA2815536C (sl)
DK (1)	DK2632927T3 (sl)
ES (2)	ES2794006T3 (sl)
HK (1)	HK1223104A1 (sl)
HR (1)	HRP20160305T1 (sl)
HU (1)	HUE027317T2 (sl)
IL (1)	IL225926A (sl)
MX (1)	MX336381B (sl)
PL (1)	PL2632927T3 (sl)
RS (1)	RS54750B1 (sl)
SI (1)	SI2632927T1 (sl)
SM (1)	SMT201600141B (sl)
WO (1)	WO2012058065A1 (sl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103068830B (zh)	2010-04-22	2016-06-29	马尔斯公司	精氨酸酶抑制剂及其治疗应用
BR112013003045B1 (pt)	2010-08-10	2021-08-31	Rempex Pharmaceuticals, Inc.	Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
ES2794006T3 (es)	2010-10-26	2020-11-17	Mars Inc	Inhibidores de arginasa como agentes terapéuticos
US9200011B2 (en) *	2012-04-18	2015-12-01	Mars, Incorporated	Ring constrained analogs as arginase inhibitors
CA2894891A1 (en)	2013-01-04	2014-07-10	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
CA2944903A1 (en) *	2014-04-24	2015-10-29	Dana-Farber Cancer Institute, Inc.	Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US9687497B1 (en)	2014-05-05	2017-06-27	Rempex Pharmaceuticals, Inc.	Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr)	2014-05-05	2019-12-31	Rempex Pharmaceuticals Inc	Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko)	2014-05-19	2017-01-18	렘펙스 파머수티클스 인코퍼레이티드	보론산 유도체 및 그의 치료적 용도
EP3164406B1 (en)	2014-07-01	2024-12-25	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en)	2014-11-18	2016-05-26	Rempex Pharmaceuticals, Inc.	Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl)	2014-12-29	2016-07-04	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
US20180051041A1 (en) *	2015-03-17	2018-02-22	Rempex Pharmaceuticals, Inc.	Boronic acid derivatives and therapeutic uses thereof
KR20180021117A (ko) *	2015-06-23	2018-02-28	칼리테라 바이오사이언시즈, 인코포레이티드	아르기나제 활성 억제를 위한 조성물 및 방법
SG10201912736UA (en)	2015-10-01	2020-02-27	Potenza Therapeutics Inc	Anti-tigit antigen-binding proteins and methods of use thereof
PL3368541T3 (pl) *	2015-10-30	2020-11-02	Calithera Biosciences, Inc.	Kompozycje i sposoby hamowania aktywności arginazy
PL417066A1 (pl)	2016-05-04	2017-11-06	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10294249B2 (en)	2016-06-30	2019-05-21	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
MX2019005402A (es)	2016-11-08	2019-12-05	Calithera Biosciences Inc	Terapias de combinacion del inhibidor de arginasa.
PL3559009T3 (pl)	2016-12-22	2021-10-25	Calithera Biosciences, Inc.	Kompozycje i sposoby hamowania aktywności arginazy
WO2018166855A1 (en)	2017-03-16	2018-09-20	Basf Se	Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar)	2017-03-30	2019-09-03	Potenza Therapeutics Inc	بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CR20190562A (es) *	2017-05-12	2020-03-04	Calithera Biosciences Inc	Método para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
US11286270B2 (en)	2017-10-11	2022-03-29	Qpex Biopharma, Inc.	Boronic acid derivatives and synthesis thereof
WO2019120296A1 (en) *	2017-12-22	2019-06-27	Guangdong Newopp Biopharmaceuticals Co., Ltd.	Heterocyclic compounds as arginase inhibitors
CN111712302B (zh)	2018-02-17	2023-09-19	阿斯利康(瑞典)有限公司	精氨酸酶抑制剂及其使用方法
CA3091805A1 (en) *	2018-03-05	2019-09-12	Arcus Biosciences, Inc.	Arginase inhibitors
US12215116B2 (en) *	2018-03-13	2025-02-04	Merck Sharp & Dohme Llc	Arginase inhibitors and methods of use
CA3094939A1 (en) *	2018-03-29	2019-10-03	Oncoarendi Therapeutics S.A.	Dipeptide piperidine derivatives
EP3781576B1 (en)	2018-04-20	2024-06-12	Qpex Biopharma, Inc.	Boronic acid derivatives and therapeutic uses thereof
CN111770756B (zh) *	2018-04-27	2023-03-31	四川科伦博泰生物医药股份有限公司	非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) *	2018-05-18	2019-11-21	四川科伦博泰生物医药股份有限公司	非天然氨基酸类衍生物、其制备方法及用途
EP3810615A4 (en)	2018-06-20	2022-03-30	Merck Sharp & Dohme Corp.	ARGINASE INHIBITORS AND METHODS OF USE
CA3120196A1 (en)	2018-11-16	2020-05-22	Arcus Biosciences, Inc.	Inhibitors of arg1 and/or arg2
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
EP3897622A4 (en) *	2018-12-18	2022-09-28	Merck Sharp & Dohme Corp.	Arginase inhibitors and methods of use
WO2020160707A1 (en) *	2019-02-06	2020-08-13	Guangdong Newopp Biopharmaceuticals Co., Ltd.	Alkylboronic acids as arginase inhibitors
IL285108B2 (en) *	2019-02-08	2024-10-01	Astrazeneca Ab	Arginase inhibitors and methods of use thereof
MX2022000904A (es) *	2019-07-23	2022-05-02	Astrazeneca Ab	Inhibidores de arginasa y métodos de uso de estos.
CN110734456A (zh) *	2019-11-06	2020-01-31	南京谷睿生物科技有限公司	一种化合物及其制备方法和医药上的应用
WO2021141751A1 (en) *	2020-01-07	2021-07-15	Merck Sharp & Dohme Corp.	Arginase inhibitors and methods of use
WO2021257863A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en)	2020-06-19	2023-07-04	Incyte Corporation	Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en)	2020-07-02	2023-09-26	Incyte Corporation	Tricyclic pyridone compounds as JAK2 V617F inhibitors
HRP20250814T1 (hr)	2020-07-02	2025-09-12	Incyte Corporation	Spojevi tricikličke uree kao jak2 v617f inhibitori
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en)	2020-12-21	2022-06-30	Incyte Corporation	Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh)	2020-12-22	2022-08-01	波蘭商昂科艾倫迪治療法股份公司	精胺酸酶抑制劑及其使用方法
CA3211748A1 (en)	2021-02-25	2022-09-01	Incyte Corporation	Spirocyclic lactams as jak2 v617f inhibitors
WO2023283332A1 (en) *	2021-07-07	2023-01-12	Emory University	Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
US20250099408A1 (en)	2022-01-21	2025-03-27	Sammy Oyoo OPIYO	Improved suramin methods and compositions
IL315647A (en)	2022-03-17	2024-11-01	Incyte Corp	Tricyclic urea compounds as Jak2 and 617f inhibitors
WO2024086273A1 (en)	2022-10-21	2024-04-25	Incyte Corporation	Tricyclic urea compounds as jak2 v617f inhibitors
US20240317744A1 (en)	2023-03-13	2024-09-26	Incyte Corporation	Bicyclic Ureas As Kinase Inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1009890A (en)	1911-02-09	1911-11-28	Michael F Brauer	Dumping attachment for headers.
US1006597A (en)	1911-05-26	1911-10-24	Rail Joint Co	Insulated rail-joint.
US4172896A (en)	1978-06-05	1979-10-30	Dainippon Pharmaceutical Co., Ltd.	Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en)	1992-08-14	1992-09-30	Wellcome Found	Controlled released tablets
US5358970A (en)	1993-08-12	1994-10-25	Burroughs Wellcome Co.	Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en)	1993-07-30	1996-07-30	Glaxo Wellcome Inc.	Stabilized Pharmaceutical
DK1348427T3 (da)	1997-07-29	2008-06-30	Alcon Lab Inc	Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
EP1049660A1 (en)	1997-10-10	2000-11-08	The Trustees Of The University Of Pennsylvania	Compositions and methods for inhibiting arginase activity
US20040063666A1 (en)	1998-10-09	2004-04-01	David Christianson	Compositions for inhibiting arginase activity
JP2004502948A (ja)	2000-07-06	2004-01-29	ファル　ダイアグノスティクス	アルギニン化合物の検出のための方法及びキット
CA2431080A1 (en)	2003-06-02	2004-12-02	Catherine Adele O'brien	Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2007005620A2 (en)	2005-07-01	2007-01-11	The Johns Hopkins University	Arginase ii: a target treatment of aging heart and heart failure
ES2633094T3 (es)	2006-11-21	2017-09-19	Rijksuniversiteit Groningen	Uso de inhibidores de arginasa en el tratamiento del asma y rinitis alérgica
CN101755130B (zh)	2007-07-12	2012-10-17	山洋电气株式会社	双重反转式轴流鼓风机
US20090118243A1 (en)	2007-10-12	2009-05-07	Resolvyx Pharmaceuticals, Inc.	Compositions and methods for the treatment of ophthalmic conditions
US20110129456A1 (en)	2008-05-05	2011-06-02	Yaolin Wang	Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
PL2389352T3 (pl) *	2009-01-26	2019-10-31	Univ Pennsylvania	Inhibitory arginazy oraz sposoby zastosowania
CN103068830B (zh)	2010-04-22	2016-06-29	马尔斯公司	精氨酸酶抑制剂及其治疗应用
ES2794006T3 (es)	2010-10-26	2020-11-17	Mars Inc	Inhibidores de arginasa como agentes terapéuticos
US8894970B2 (en)	2010-12-31	2014-11-25	Corridor Pharmaceuticals, Inc.	Arginase inhibitors and methods of use thereof
AU2012326109A1 (en)	2011-10-19	2014-05-29	Mars, Incorporated	Inhibitors of arginase and their therapeutic applications
CN104394869A (zh)	2011-10-20	2015-03-04	葛兰素史密斯克莱有限责任公司	用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
US9200011B2 (en)	2012-04-18	2015-12-01	Mars, Incorporated	Ring constrained analogs as arginase inhibitors
CA2890111A1 (en)	2012-11-02	2014-05-08	Pharmacyclics, Inc.	Tec family kinase inhibitor adjuvant therapy
EA029126B1 (ru)	2013-07-01	2018-02-28	Бристол-Майерс Сквибб Компани	Ингибиторы ido
TWI660739B (zh)	2013-10-25	2019-06-01	製藥公司	使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
CN105879030A (zh)	2014-09-30	2016-08-24	复旦大学	治疗肿瘤的增效药物复合物及其制备方法
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CN107405404A (zh)	2015-03-20	2017-11-28	塞米·欧尤·奥皮约	苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
KR20180021117A (ko)	2015-06-23	2018-02-28	칼리테라 바이오사이언시즈, 인코포레이티드	아르기나제 활성 억제를 위한 조성물 및 방법
PL3368541T3 (pl)	2015-10-30	2020-11-02	Calithera Biosciences, Inc.	Kompozycje i sposoby hamowania aktywności arginazy
PL417066A1 (pl)	2016-05-04	2017-11-06	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL3559009T3 (pl)	2016-12-22	2021-10-25	Calithera Biosciences, Inc.	Kompozycje i sposoby hamowania aktywności arginazy
CR20190562A (es)	2017-05-12	2020-03-04	Calithera Biosciences Inc	Método para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida

2011
- 2011-10-19 ES ES16150285T patent/ES2794006T3/es active Active
- 2011-10-19 CA CA2815536A patent/CA2815536C/en active Active
- 2011-10-19 US US13/276,806 patent/US9233985B2/en active Active
- 2011-10-19 EP EP20162218.0A patent/EP3719024A1/en active Pending
- 2011-10-19 HR HRP20160305TT patent/HRP20160305T1/hr unknown
- 2011-10-19 HU HUE11779904A patent/HUE027317T2/en unknown
- 2011-10-19 WO PCT/US2011/056844 patent/WO2012058065A1/en not_active Ceased
- 2011-10-19 CN CN201610322649.4A patent/CN106008569B9/zh not_active Expired - Fee Related
- 2011-10-19 EP EP11779904.9A patent/EP2632927B1/en active Active
- 2011-10-19 MX MX2013004491A patent/MX336381B/es unknown
- 2011-10-19 CN CN201180057717.4A patent/CN103249737B/zh not_active Expired - Fee Related
- 2011-10-19 EP EP16150285.1A patent/EP3034509B1/en active Active
- 2011-10-19 PL PL11779904.9T patent/PL2632927T3/pl unknown
- 2011-10-19 DK DK11779904.9T patent/DK2632927T3/en active
- 2011-10-19 BR BR112013010099-0A patent/BR112013010099B1/pt not_active IP Right Cessation
- 2011-10-19 ES ES11779904.9T patent/ES2568680T3/es active Active
- 2011-10-19 AU AU2011320732A patent/AU2011320732B2/en not_active Ceased
- 2011-10-19 RS RS20160243A patent/RS54750B1/sr unknown
- 2011-10-19 SI SI201130766A patent/SI2632927T1/sl unknown
- 2011-10-19 JP JP2013536669A patent/JP5909239B2/ja active Active
2013
- 2013-04-24 IL IL225926A patent/IL225926A/en active IP Right Grant
2015
- 2015-02-04 US US14/614,115 patent/US9440995B2/en active Active
2016
- 2016-05-19 SM SM201600141T patent/SMT201600141B/it unknown
- 2016-07-12 US US15/207,902 patent/US10098902B2/en active Active
- 2016-09-23 HK HK16111212.1A patent/HK1223104A1/en unknown
2018
- 2018-08-21 US US16/107,087 patent/US10603330B2/en not_active Expired - Fee Related
2020
- 2020-02-19 US US16/794,905 patent/US11389464B2/en active Active

Also Published As

Publication number	Publication date
CN106008569B9 (zh)	2020-05-22
US10603330B2 (en)	2020-03-31
HK1223104A1 (en)	2017-07-21
RS54750B1 (sr)	2016-10-31
BR112013010099B1 (pt)	2021-08-10
MX2013004491A (es)	2013-11-04
CA2815536C (en)	2019-10-01
US11389464B2 (en)	2022-07-19
EP2632927B1 (en)	2016-02-10
WO2012058065A1 (en)	2012-05-03
BR112013010099A2 (pt)	2016-09-06
PL2632927T3 (pl)	2016-09-30
CN103249737B (zh)	2016-06-08
US20150191492A1 (en)	2015-07-09
HRP20160305T1 (hr)	2016-07-01
ES2568680T3 (es)	2016-05-03
MX336381B (es)	2016-01-18
US20170000808A1 (en)	2017-01-05
US9440995B2 (en)	2016-09-13
CN106008569A (zh)	2016-10-12
ES2794006T3 (es)	2020-11-17
US20200246362A1 (en)	2020-08-06
US20190054101A1 (en)	2019-02-21
EP2632927A1 (en)	2013-09-04
AU2011320732B2 (en)	2018-07-05
US10098902B2 (en)	2018-10-16
HUE027317T2 (en)	2016-10-28
IL225926A (en)	2016-09-29
US20120129806A1 (en)	2012-05-24
CN106008569B (zh)	2020-04-03
EP3034509B1 (en)	2020-04-22
US9233985B2 (en)	2016-01-12
JP2013542223A (ja)	2013-11-21
HK1225390A1 (zh)	2017-09-08
SMT201600141B (it)	2016-07-01
CN103249737A (zh)	2013-08-14
CA2815536A1 (en)	2012-05-03
AU2011320732A1 (en)	2013-11-21
EP3034509A1 (en)	2016-06-22
DK2632927T3 (en)	2016-04-11
EP3719024A1 (en)	2020-10-07
IL225926A0 (en)	2013-06-27
JP5909239B2 (ja)	2016-04-26

Publication	Publication Date	Title
SI2632927T1 (sl)	2016-08-31	Boronati kot inhibitorji arginaze
TWI560172B (en)	2016-12-01	Neprilysin inhibitors
ZA201304205B (en)	2014-02-26	Neprilysin inhibitors
GB201004179D0 (en)	2010-04-28	Enzyme inhibitors
ZA201305826B (en)	2014-04-30	Substituted amminobutyric derivatives as neprilysin inhibitors
ZA201304208B (en)	2014-02-26	Neprilysin inhibitors
ZA201306580B (en)	2014-05-28	Cyclopropylamines as lsd1 inhibitors
GB201004178D0 (en)	2010-04-28	Enzyme inhibitors
PL2563771T3 (pl)	2016-06-30	Związki inhibitora metaloenzymu
GB201004311D0 (en)	2010-04-28	New enzyme inhibitor compounds
GB201016880D0 (en)	2010-11-17	Phosphodiesterase inhibitors
AP3529A (en)	2016-01-11	Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
ZA201206456B (en)	2013-05-29	Uses of dgati inhibitors
ZA201303360B (en)	2014-07-30	Kat ii inhibitors
GB201018996D0 (en)	2010-12-22	Novel ROCK inhibitors
EP2521451A4 (en)	2013-08-21	INHIBITORS OF THE HEDGEHOG PATH
EP2632903A4 (en)	2014-11-26	METALLOENZYMHEMMERVERBINDUNGEN
GB201020798D0 (en)	2011-01-19	Corrosion inhibitors
EP2651905A4 (en)	2014-05-07	METALLOENZYMHEMMERVERBINDUNGEN
ZA201303412B (en)	2014-07-30	Kat ii inhibitors
GB201113689D0 (en)	2011-09-21	Novel PDE4 inhibitors
PL2558462T3 (pl)	2015-03-31	Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
GB201003936D0 (en)	2010-04-21	Novel inhibitors
GB201006605D0 (en)	2010-06-02	Novel inhibitors
GB201003502D0 (en)	2010-04-14	Novel inhibitors